Wutah pendapatan taun lumaku: Fennec (FENC)

Logo perusahaan publik fennecpharma.com (FENC)

The diversification of pediatric hearing protection programs during chemotherapy impacts the TTM year-over-year sales growth rate for Fennec Pharmaceuticals (FENC), where the 70.90 metric serves as the target level. Financial stability is based on the creation of an irreplaceable treatment ecosystem. The monopoly status of Pedmark and FDA orphan drug privileges establish insurmountable barriers to entry for competitors, ensuring long-term protection of the market niche.

Fennec Pharmaceuticals (FENC): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 17.11.2026

Fennec Pharmaceuticals - rincian analitis lan metrik utama (FENC)

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:Fennec Pharmaceuticals Inc
Produk merek Fennec

Fennec Pharmaceuticals' status as a monopolist in pediatric hearing protection during chemotherapy creates a foundation for the stable extraction of high rents. This metric, which has reached 70.90, measures the rate of revenue change over the last 12 months relative to the same period last year, allowing for an assessment of the drug's commercialization speed and the business's long-term scaling potential through the TTM revenue growth trajectory compared to the previous year.

Karo sapa Fennec Pharmaceuticals saingan

Incyte Pharma - Wutah dodolan YoY sajrone rolas wulan kepungkur|HUTCHMED Corp - Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku Nuvation Bio Inc.|DAWN: Wutah dodolan YoY (TTM)|Tingkat wutah pendapatan YoY sajrone rolas wulan kepungkur Monopar Pharma MNPR|Wutah pendapatan YoY sajrone 12 wulan kepungkur INBX|Wutah pendapatan taun lumaku I-Mab Biopharma IMAB|Wutah pendapatan YoY sajrone 12 wulan kepungkur HRTX (Heron)|NVCT (Nuvectis Pharma) - Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Coherus Biosciences - Wutah pendapatan YoY sajrone 12 wulan kepungkur|Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur CRBP (Corbus Pharmaceuticals Holdings)|Cardiff Oncology - Wutah dodolan YoY (TTM)|Dinamika pendapatan YoY sajrone rolas wulan kepungkur BYSI (BeyondSpring Pharma)|BCAB: Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku lixte.com (LIXT)|Wutah dodolan YoY sajrone rolas wulan kepungkur citiuspharma.com|CLRB: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY (TTM) BLRX|Wutah dodolan YoY (TTM) Can-Fite (CANF)|Wutah dodolan YoY sajrone rolas wulan kepungkur Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Wutah dodolan taun lumaku|SLXN: Wutah pendapatan YoY sajrone 12 wulan kepungkur|Wutah pendapatan taun lumaku NuCana|CMRX: Wutah dodolan YoY (TTM)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Wutah dodolan YoY (TTM)|KRON: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY sajrone rolas wulan kepungkur Kintara (KTRA)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Oncternal ONCT|Portage Biotech - Wutah pendapatan YoY sajrone 12 wulan kepungkur